Scientific Computing and Data / Research Data Services / Data Ark: Data Commons / Kidney Precision Medicine Project (KPMP)

Kidney Precision Medicine Project (KPMP)

Overview

Introduction

The Kidney Precision Medicine Project (KPMP) is a prospective cohort study, whose goal is to use deep molecular phenotypes of kidney biopsies, along with longitudinally collected clinical phenotypic data, in order to develop new disease ontologies, classification systems, and treatments for acute kidney injury (AKI) and chronic kidney disease (CKD).

For each participant, kidney tissue is obtained for molecular phenotyping and clinical diagnosis. In addition to the kidney biopsy tissue, the study collects baseline (time of biopsy) and longitudinal biospecimens (including urine, plasma, serum, DNA, and stool) and demographic, clinical, and laboratory data.

‍

Participant Population

The KPMP is focusing on participants with acute and chronic kidney disease, who account for a large portion of the public health concern as reported by research and federal data.

CKD

• High priority populations include CKD in the setting of diabetes (diabetic kidney disease, DKD) and hypertension-associated CKD (H-CKD).

DM-R

• A special population of people with long-standing type 1 diabetes (more than 25 years) who remain free of clinically-evident DKD (i.e. diabetes mellitus-resilient (DM-R) individuals also known as “Resistors”) will also be included. Study of the DM-R population using KPMP protocols offers a unique opportunity to identify protective factors against complications of diabetes mellitus.

AKI

• The focus will be on acute intrinsic non-glomerular disease, primarily on acute tubular necrosis (ATN).

‍

Inclusion / Exclusion Criteria

Inclusion:

• Diabetic Kidney Disease (Type 1 or 2)
• Hypertensive Kidney Disease
• Acute Kidney Injury
• Patient has had diabetes for many years but no clinical indications of CKD

Exclusion:

• Age (under 18)
• Glomerular disease, kidney transplant, malignancy, pregnancy
• Increased biopsy complication risk

For more specific details regarding inclusion and exclusion criteria for our various study populations, see the full clinical protocol on the KPMP website.

‍

Cite KPMP in your publications

The following citation must be used when citing KPMP data. KPMP follows the AMA standard for its citations.

‍The results here are in whole or part based upon data generated by the Kidney Precision Medicine Project. Accessed Month Day, Year. https://www.kpmp.org.

The Kidney Precision Medicine Project (KPMP) is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) through the following grants: U01DK133081, U01DK133091, U01DK133092, U01DK133093, U01DK133095, U01DK133097, U01DK114866, U01DK114908, U01DK133090, U01DK133113, U01DK133766, U01DK133768, U01DK114907, U01DK114920, U01DK114923, U01DK114933, U24DK114886, UH3DK114926, UH3DK114861, UH3DK114915, and UH3DK114937. We gratefully acknowledge the essential contributions of our patient participants and the support of the American public through their tax dollars.

‍NOTE: Remember to replace “Accessed Month Day, Year” with the correct specific details.

What Is Hosted Under Data Ark?

Access

As has been our directive from the start of KPMP we want to make our data accessible to the greater kidney community. We retain control of data that are deemed to be potentially identifiable, though the vast majority of the data in the Atlas are openly accessible. This means users are capable of downloading at the click of a button.

The controlled access data has a well-established workflow.

• When users select controlled access data in the Kidney Tissue Atlas (KTA) Repository, they are immediately given a link that will get them started on the process of completing a Data Use Agreement (you must be logged in through the Mount Sinai campus network or secure remote VPN).
• The request starts with the Central Hub at MSSM, where the data request information is reviewed, and the KPMP standard DUA is sent to the requesting institution for review and completion on their part.
• The signed DUA is then sent back to the Central Hub where final approvals are completed between the two institutions. The substance of the data request is then communicated to the Kidney Mapping Atlas Project (KMAP) team and/or the Central Data Coordination Center (CDCC) to complete the request.
• The CDCC manages the clinical data requests while KMAP is responsible for the controlled access omics data files.

After granted access, you can access the data by going to the folder on Minerva directly. To get the path variable, you can load the module by issuing the command $ module load dataark.

Data Ark Data Sets

Please visit the Data Ark Data Set webpage to explore other data sets.